Daratumumab

Johnson & Johnson (J&J) has received approval from the European Commission (EC) for its subcutaneous (SC) Darzalex (daratumumab)-based quadruplet regimen in newly diagnosed multiple myeloma (MM). The SC formulation of Darzalex is now authorised for use in combination with bortezomib, lenalidomide and dexamethasone (VRd) in the frontline setting, regardless of patients’ transplant eligibility. More than 35,000 people in the EU were diagnosed with MM, a currently incurable blood cancer, in 2022 alone. Darzalex is a monoclonal antibody that is designed to inhibit tumour cell growth by attaching to the CD38 protein, which is found in high amounts on abnormal white blood cells in MM. The drug is now approved for nine MM indications, including as part of treatment regimens for newly diagnosed patients who are eligible or ineligible for an autologous stem-cell transplant (ASCT). The EC’s latest decision follows a recent recommendation from the European Medicines Agency’s human medicines committee and was supported by positive results from the phase 3 CEPHEUS study, which compared Darzalex SC-VRd against VRd alone in newly diagnosed MM patients who were transplant ineligible or for whom ASCT was not planned as initial therapy. At a median follow-up of 59 months, the primary endpoint was met, with an overall minimal residual disease (MRD)-negativity rate of 60.9% for patients randomised to receive Darzalex SC-VRd compared to 39.4% for those in the VRd cohort. The amount of patients achieving sustained MRD-negativity of at least 12 months almost doubled with Darzalex SC-VRd compared to VRd, at 48.7% versus 26.3%, and J&J’s regimen significantly increased the depth of response with higher rates of complete response or better. The quadruplet regimen also reduced the risk of progression or death by 43%, and the overall safety profile of Darzalex SC-VRd was consistent with the known profiles for Darzalex SC and VRd. Jordan Schecter, vice president, disease area leader, multiple myeloma, J&J Innovative Medicine, said: “This landmark approval enables us to offer all patient populations access regardless of age, fitness or risk to a Darzalex-based triplet or quadruplet regimen in the frontline setting – a critical step towards our ultimate goal of delivering a functional cure.”

2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn’s disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, Company maintains Full-Year 2025 adjusted reported EPS4 outlook of 6.2%* growth at the mid-point NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition.” Overall financial results Q1 ($ in Millions, expect EPS) 2025 2024 % Change Reported Sales $21,893 $ 21,383 2.4% Net Earnings $10,999 $3,255 237.9% EPS (diluted) $4.54 $1.34 238.8% Q1 Non-GAAP* ($ in Millions, except EPS) 2025 2024 % Change Operational Sales1,2 4.2% Adjusted Operational Sales1,3 3.3% Adjusted Net Earnings1,4 $6,706 $6,580 1.9% Adjusted EPS (diluted)1,4 $2.77 $2.71 2.2% Free Cash Flow6,7 ~$3,400 $2,850 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine 6 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 7 First-quarter 2025 is estimated as of April 15, 2025 Regional sales results Q1 % Change ($ in Millions) 2025 2024 Reported Operational1,2 Currency Adjusted Operational1,3 U.S. $12,305 $11,620 5.9% 5.9 - 4.4 International 9,588 9,763 (1.8) 2.1 (3.9) 1.9 Worldwide $21,893 $21,383 2.4% 4.2 (1.8) 3.3 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Segment sales results Q1 % Change ($ in Millions) 2025 2024 Reported Operational1,2 Currency Adjusted Operational1,3 Innovative Medicine $13,873 $13,562 2.3% 4.2 (1.9) 4.4 MedTech 8,020 7,821 2.5 4.1 (1.6) 1.3 Worldwide $21,893 $21,383 2.4% 4.2 (1.8) 3.3 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency First-Quarter 2025 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 4.2%* driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, SPRAVATO in Neuroscience, and XARELTO in Cardiovascular/Metabolism/Other. Growth was partially offset by an approximate (810) basis points impact from STELARA in Immunology. MedTech MedTech worldwide operational sales grew 4.1%*, with net acquisitions and divestitures positively impacting growth by 2.8%. Growth was driven primarily by Abiomed in Cardiovascular and wound closure products in General Surgery. Growth was partially offset by Spine, Sports & Other in Orthopaedics. Full-year 2025 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) April 2025 January 2025 Adjusted Operational Sales1,2,5 Change vs. Prior Year / Mid-point 2.0% – 3.0% / 2.5% 2.0% – 3.0% / 2.5% Operational Sales2,5 / Mid-point Change vs. Prior Year / Mid-point $91.6B – $92.4B / $92.0B 3.3% – 4.3% / 3.8% $90.9B – $91.7B / $91.3B 2.5% – 3.5% / 3.0% Estimated Reported Sales3,5/ Mid-point Change vs. Prior Year / Mid-point $91.0B – $91.8B / $91.4B 2.6% – 3.6% / 3.1% $89.2B – $90.0B / $89.6B 0.5% – 1.5% / 1.0% Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% $10.75 – $10.95 / $10.85 7.7% – 9.7% / 8.7% Adjusted EPS (Diluted)3,4 / Mid-point Change vs. Prior Year / Mid-point $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: April 2025 = $1.10 and January 2025 = $1.04 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Other modeling considerations will be provided on the webcast. Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and www.factsabouttalc.com. Regulatory European Commission approves subcutaneous RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer1 Press Release European Commission approves Johnson & Johnson’s subcutaneous DARZALEX (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility1 Press Release U.S. FDA approves TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease Press Release Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation Press Release Data Releases Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA Robotic Surgical System1 Press Release Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill1 Press Release Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)1 Press Release TREMFYA (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis1 Press Release Johnson & Johnson MedTech to Highlight Latest Advancements in Heart Disease Treatment with Impella at ACC.25 Press Release RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer Press Release New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG) Press Release RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025 Press Release Johnson & Johnson MedTech Showcases New Era of Digital Orthopaedics at AAOS 2025 Press Release Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients Press Release Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis Press Release TREMFYA (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis Press Release New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases Press Release Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology Press Release Product Launch Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions Press Release Other Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership1 Press Release Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims1 Press Release Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years Press Release Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations Press Release Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations. About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com. Non-GAAP financial measures: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results. Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results. Note to investors concerning forward-looking statements: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Percent Change 2025 2024 Total Operations Currency $ 8,092 7,612 6.3 % 6.3 - 5,781 5,950 (2.9 ) 1.5 (4.4 ) 13,873 13,562 2.3 4.2 (1.9 ) 4,213 4,008 5.1 5.1 - 3,807 3,813 (0.2 ) 3.0 (3.2 ) 8,020 7,821 2.5 4.1 (1.6 ) 12,305 11,620 5.9 5.9 - 9,588 9,763 (1.8 ) 2.1 (3.9 ) $ 21,893 21,383 2.4 % 4.2 (1.8 ) Percent Change 2025 2024 Total Operations Currency $ 12,305 11,620 5.9 % 5.9 - 5,110 5,163 (1.0 ) 2.2 (3.2 ) 1,167 1,194 (2.3 ) 9.2 (11.5 ) 3,311 3,406 (2.8 ) (0.6 ) (2.2 ) 9,588 9,763 (1.8 ) 2.1 (3.9 ) $ 21,893 21,383 2.4 % 4.2 (1.8 ) 2025 2024 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) $ 21,893 100.0 $ 21,383 100.0 2.4 7,357 33.6 6,511 30.4 13.0 14,536 66.4 14,872 69.6 (2.3 ) 5,112 23.3 5,257 24.6 (2.8 ) 3,225 14.7 3,542 16.6 (8.9 ) (128 ) (0.6 ) (209 ) (1.0 ) (7,321 ) (33.4 ) 2,404 11.2 17 0.1 164 0.8 13,631 62.3 3,714 17.4 267.0 2,632 12.1 459 2.2 473.4 $ 10,999 50.2 $ 3,255 15.2 237.9 $ 4.54 $ 1.34 238.8 2,423.8 2,430.1 19.3 % 12.4 % $ 8,011 36.6 $ 7,877 36.8 1.7 $ 6,706 30.6 $ 6,580 30.8 1.9 $ 2.77 $ 2.71 2.2 16.3 % 16.5 % 2025 2024 $10,999 $3,255 (6,966) 2,726 1,120 1,078 55 171 132 148 39 (20) - 51 - 9 1,315 (856) 12 18 $6,706 $6,580 2,423.8 2,430.1 $2.77 $2.71 $2.81 1 2 2.3% 2.5% 2.4% 6.3% 5.1% 5.9% (2.9)% (0.2)% (1.8)% (1.9) (1.6) (1.8) - - - (4.4) (3.2) (3.9) 4.2% 4.1% 4.2% 6.3% 5.1% 5.9% 1.5% 3.0% 2.1% (3.3) (1.2) (5.1) (1.8) (1.4) (0.5) 0.2 0.5 0.3 0.0 0.9 0.3 0.4 0.2 0.3 4.4% 1.3% 3.3% 6.3% 0.9% 4.4% 1.9% 1.8% 1.9% REPORTED SALES vs. PRIOR PERIOD ($MM) 2025 2024 Reported Operational (1) Currency $ 3,013 2,383 26.4 % 26.4 % - 2,664 2,430 9.6 % 14.4 % -4.8 % 5,678 4,814 17.9 % 20.4 % -2.5 % 318 140 * * - 51 16 * * * 369 157 * * * 1,829 1,464 24.9 % 24.9 % - 1,409 1,228 14.7 % 19.8 % -5.1 % 3,237 2,692 20.3 % 22.5 % -2.2 % 292 285 2.5 % 2.5 % - 479 404 18.5 % 23.1 % -4.6 % 771 689 11.9 % 14.6 % -2.7 % 235 265 -11.5 % -11.5 % - 474 518 -8.5 % -4.2 % -4.3 % 709 784 -9.5 % -6.7 % -2.8 % 113 36 * * - 28 11 * * * 141 47 * * * 68 50 35.2 % 35.2 % - 18 8 * * * 86 58 48.4 % 50.2 % -1.8 % 105 101 4.9 % 4.9 % - 46 33 38.8 % 45.9 % -7.1 % 151 133 13.3 % 15.0 % -1.7 % 7 9 -24.3 % -24.3 % - 118 172 -31.3 % -28.5 % -2.8 % 125 181 -30.9 % -28.3 % -2.6 % 47 33 42.9 % 42.9 % - 42 41 4.6 % 10.1 % -5.5 % 89 73 21.7 % 24.7 % -3.0 % REPORTED SALES vs. PRIOR PERIOD ($MM) 2025 2024 Reported Operational (1) Currency 2,196 2,453 -10.5 % -10.5 % - 1,510 1,794 -15.8 % -11.5 % -4.3 % 3,707 4,247 -12.7 % -10.9 % -1.8 % 314 266 18.1 % 18.1 % - 10 27 -64.2 % -64.2 % - 143 141 1.3 % 6.8 % -5.5 % 467 434 7.5 % 9.3 % -1.8 % 292 254 14.8 % 14.8 % - 366 299 22.4 % 29.7 % -7.3 % 659 554 18.9 % 22.9 % -4.0 % 981 1,396 -29.8 % -29.8 % - 644 1,055 -38.9 % -35.8 % -3.1 % 1,625 2,451 -33.7 % -32.3 % -1.4 % 599 509 17.6 % 17.6 % - 356 299 19.2 % 24.4 % -5.2 % 956 808 18.2 % 20.1 % -1.9 % 1 0 * * - 0 0 - - - 1 0 * * - 968 1,054 -8.1 % -8.1 % - 679 749 -9.3 % -5.5 % -3.8 % 1,647 1,803 -8.6 % -7.0 % -1.6 % 38 41 -7.4 % -7.4 % - 110 136 -18.9 % -15.2 % -3.7 % 148 177 -16.3 % -13.4 % -2.9 % 625 765 -18.2 % -18.2 % - 277 292 -4.9 % -1.1 % -3.8 % 903 1,056 -14.5 % -13.5 % -1.0 % 276 191 45.0 % 45.0 % - 43 34 25.0 % 31.7 % -6.7 % 320 225 41.9 % 42.9 % -1.0 % 28 58 -50.6 % -50.6 % - 248 287 -13.4 % -9.8 % -3.6 % 277 345 -19.6 % -16.7 % -2.9 % REPORTED SALES vs. PRIOR PERIOD ($MM) 2025 2024 Reported Operational (1) Currency 744 766 -2.9 % -2.9 % - 281 283 -0.6 % 3.2 % -3.8 % 1,025 1,049 -2.3 % -1.2 % -1.1 % 363 356 2.1 % 2.1 % - 159 169 -6.0 % -2.5 % -3.5 % 522 524 -0.5 % 0.6 % -1.1 % 365 392 -6.9 % -6.9 % - 86 76 13.4 % 17.5 % -4.1 % 451 468 -3.6 % -2.9 % -0.7 % 15 18 -12.7 % -12.7 % - 37 39 -4.6 % -0.3 % -4.3 % 52 56 -7.2 % -4.3 % -2.9 % 315 324 -2.8 % -2.8 % - 487 497 -1.9 % 1.9 % -3.8 % 802 821 -2.2 % 0.1 % -2.3 % 8 8 -1.3 % -1.3 % - 350 315 11.0 % 14.7 % -3.7 % 358 323 10.7 % 14.3 % -3.6 % 305 314 -2.9 % -2.9 % - 98 104 -6.2 % -0.6 % -5.6 % 403 418 -3.7 % -2.3 % -1.4 % 2 2 7.7 % 7.7 % - 39 77 -48.8 % -47.0 % -1.8 % 41 78 -47.6 % -45.9 % -1.7 % 855 631 35.4 % 35.4 % - 158 197 -19.7 % -15.3 % -4.4 % 1,013 829 22.3 % 23.4 % -1.1 % 690 518 33.3 % 33.3 % - - - - - - 690 518 33.3 % 33.3 % - 165 114 45.0 % 45.0 % - 158 197 -19.7 % -15.3 % -4.4 % 323 311 3.9 % 6.7 % -2.8 % 8,092 7,612 6.3 % 6.3 % - 5,781 5,950 -2.9 % 1.5 % -4.4 % $ 13,873 13,562 2.3 % 4.2 % -1.9 % REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change 2025 2024 Reported Operational (1) Currency $ 1,261 1,025 23.0 % 23.0 % - 842 781 7.8 % 10.7 % -2.9 % 2,103 1,806 16.4 % 17.7 % -1.3 % 684 692 -1.1 % -1.1 % - 638 652 -2.0 % 0.7 % -2.7 % 1,323 1,344 -1.6 % -0.2 % -1.4 % 339 303 11.9 % 11.9 % - 81 67 19.7 % 23.6 % -3.9 % 420 371 13.3 % 14.0 % -0.7 % 206 - * * - 52 - * * - 258 - * * - 32 30 7.1 % 7.1 % - 72 62 15.1 % 17.4 % -2.3 % 103 92 12.5 % 14.1 % -1.6 % 1,384 1,448 -4.4 % -4.4 % - 857 892 -3.9 % -0.9 % -3.0 % 2,241 2,340 -4.2 % -3.1 % -1.1 % 263 270 -2.5 % -2.5 % - 146 152 -4.0 % -0.8 % -3.2 % 409 422 -3.1 % -1.9 % -1.2 % 231 242 -4.3 % -4.3 % - 158 160 -1.0 % 2.1 % -3.1 % 389 401 -3.0 % -1.7 % -1.3 % 502 504 -0.5 % -0.5 % - 270 261 3.7 % 7.2 % -3.5 % 772 765 0.9 % 2.1 % -1.2 % 388 432 -10.2 % -10.2 % - 283 320 -11.6 % -8.9 % -2.7 % 671 752 -10.8 % -9.7 % -1.1 % REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change 2025 2024 Reported Operational (1) Currency 1,002 987 1.5 % 1.5 % - 1,394 1,429 -2.5 % 0.8 % -3.3 % 2,396 2,416 -0.8 % 1.1 % -1.9 % 457 446 2.7 % 2.7 % - 616 641 -4.0 % -1.0 % -3.0 % 1,073 1,087 -1.2 % 0.5 % -1.7 % 544 542 0.5 % 0.5 % - 778 788 -1.2 % 2.3 % -3.5 % 1,323 1,330 -0.5 % 1.6 % -2.1 % 566 547 3.4 % 3.4 % - 713 710 0.4 % 3.9 % -3.5 % 1,279 1,258 1.7 % 3.7 % -2.0 % 452 438 3.1 % 3.1 % - 467 472 -1.1 % 2.4 % -3.5 % 919 910 1.0 % 2.7 % -1.7 % 114 110 4.3 % 4.3 % - 246 238 3.4 % 7.1 % -3.7 % 361 348 3.7 % 6.2 % -2.5 % 4,213 4,008 5.1 % 5.1 % - 3,807 3,813 -0.2 % 3.0 % -3.2 % $ 8,020 7,821 2.5 % 4.1 % -1.6 % 2023 2024 2024 Full Year Q1 Q2 Q3 Q4 Full Year 66 36 52 68 101 257 27 11 17 21 21 70 93 47 69 89 122 327 56 50 59 64 68 241 7 8 9 12 17 46 63 58 69 75 85 287 93 33 37 36 39 145 235 41 45 50 36 172 328 73 83 86 75 317 1,292 356 376 417 408 1,557 681 169 171 166 162 668 1,973 524 548 583 570 2,225 79 18 17 21 19 75 182 39 49 39 38 165 260 56 67 60 57 240 19 2 5 3 1 11 1,395 77 227 54 43 401 1,414 78 233 56 45 412 First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP $ 4,020 (649 ) 3,371 2,261 2,261 2,548 2,548 (166 ) - - - (20 ) (18 ) - (204 ) 5,210 649 - - 20 18 - 5,897 First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP $ 3,326 (471 ) (8 ) (52 ) 2,795 2,656 2,656 677 (6 ) 671 (60 ) - - (47 ) (54 ) (21 ) - (182 ) 1,421 471 - 55 112 21 - 2,080 First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP $ 11 11 195 195 - (7,206 ) - 6,966 - - - - (240 ) 7,000 - (6,966 ) - - - - 34 First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP $ 7,357 (1,120 ) (8 ) (52 ) - 6,177 5,112 5,112 3,225 (6 ) 3,219 (7,321 ) - 6,966 (30 ) (74 ) (39 ) (498 ) - - (128 ) (128 ) 17 (17 ) - 13,631 1,120 (6,966 ) 55 132 39 - 8,011 2,632 188 (1,553 ) 11 30 9 (12 ) 1,305 10,999 932 (5,413 ) 44 102 30 12 6,706 $ 3,370 (698 ) (2 ) 2,670 2,438 2,438 2,896 (7 ) 2,889 (111 ) (144 ) (47 ) 55 (247 ) 4,969 698 - 144 47 (55 ) - 9 - 5,812 $ 3,120 (380 ) (7 ) (20 ) 2,713 2,582 (4 ) 2,578 646 (18 ) (27 ) 601 (47 ) (20 ) (43 ) (22 ) (132 ) 1,520 380 - 27 61 22 51 - - 2,061 $ 21 21 237 237 - - 2,517 (2,726 ) (40 ) (13 ) (262 ) (2,775 ) - 2,726 - 40 13 - - - 4 $ 6,511 (1,078 ) (7 ) (20 ) (2 ) 5,404 5,257 (4 ) 5,253 3,542 (18 ) (27 ) (7 ) 3,490 2,404 (2,726 ) (130 ) 20 (432 ) - - (209 ) (209 ) 164 (164 ) - 3,714 1,078 2,726 171 148 (20 ) 51 9 - 7,877 459 148 627 39 38 (7 ) 9 2 (18 ) 1,297 3,255 930 2,099 132 110 (13 ) 42 7 18 6,580 Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com